These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Sequential disseminated aspergillosis and pulmonary tuberculosis in a patient treated by idelalisib for chronic lymphocytic leukemia. Lafon-Desmurs B; Monsel G; Leblond V; Papo M; Caumes E; Fekkar A; Jaureguiberry S Med Mal Infect; 2017 Jun; 47(4):293-296. PubMed ID: 27818019 [No Abstract] [Full Text] [Related]
3. Idelalisib for chronic lymphocytic leukemia. Brown JR Clin Adv Hematol Oncol; 2014 Dec; 12(12):846-8. PubMed ID: 25674842 [No Abstract] [Full Text] [Related]
4. Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial. Jones JA; Robak T; Brown JR; Awan FT; Badoux X; Coutre S; Loscertales J; Taylor K; Vandenberghe E; Wach M; Wagner-Johnston N; Ysebaert L; Dreiling L; Dubowy R; Xing G; Flinn IW; Owen C Lancet Haematol; 2017 Mar; 4(3):e114-e126. PubMed ID: 28257752 [TBL] [Abstract][Full Text] [Related]
5. Discussion: Managing Risk When Using Idelalisib. Coutre SE; Burger JA; Pagel JM Clin Adv Hematol Oncol; 2016 May; 14(5 Suppl 8):13. PubMed ID: 27168205 [No Abstract] [Full Text] [Related]
6. Management of adverse events associated with idelalisib treatment in chronic lymphocytic leukemia and follicular lymphoma: A multidisciplinary position paper. Cuneo A; Barosi G; Danesi R; Fagiuoli S; Ghia P; Marzano A; Montillo M; Poletti V; Viale P; Zinzani PL Hematol Oncol; 2019 Feb; 37(1):3-14. PubMed ID: 30187496 [TBL] [Abstract][Full Text] [Related]
8. Haematological cancer: idelalisib-targeting PI3Kδ in patients with B-cell malignancies. Burger JA; Okkenhaug K Nat Rev Clin Oncol; 2014 Apr; 11(4):184-6. PubMed ID: 24642682 [TBL] [Abstract][Full Text] [Related]
9. Multiple mucosal ulcerations caused by idelalisib. Galeone M; Antiga E Int J Dermatol; 2017 Sep; 56(9):e180-e181. PubMed ID: 28244069 [No Abstract] [Full Text] [Related]
10. Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia. Brown JR; Byrd JC; Coutre SE; Benson DM; Flinn IW; Wagner-Johnston ND; Spurgeon SE; Kahl BS; Bello C; Webb HK; Johnson DM; Peterman S; Li D; Jahn TM; Lannutti BJ; Ulrich RG; Yu AS; Miller LL; Furman RR Blood; 2014 May; 123(22):3390-7. PubMed ID: 24615777 [TBL] [Abstract][Full Text] [Related]
11. Idelalisib in Waldenström macroglobulinemia: high incidence of hepatotoxicity. Castillo JJ; Gustine JN; Meid K; Dubeau T; Yang G; Xu L; Hunter ZR; Treon SP Leuk Lymphoma; 2017 Apr; 58(4):1002-1004. PubMed ID: 27562445 [No Abstract] [Full Text] [Related]
12. Idelalisib approved for three blood cancers. Traynor K Am J Health Syst Pharm; 2014 Sep; 71(17):1430. PubMed ID: 25147161 [No Abstract] [Full Text] [Related]
13. Idelalisib induced CMV gastrointestinal disease: the need for vigilance with novel therapies. Goldring L; Kumar B; Gan TE; Low MSY Pathology; 2017 Aug; 49(5):555-557. PubMed ID: 28693750 [No Abstract] [Full Text] [Related]